Clinical trial
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage…
NCT00118053 · University of Medicine and Dentistry of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00118053 |
|---|---|
| Title | Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer |
| Official title | A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | herceptin, carboplatin, docetaxel, conventional surgery, radiation therapy |
| Enrollment | 5 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | Nov 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: